布地奈德雾化治疗在COPD急性加重期的应用被引量：62

NEBULIZED BUDESONIDE IN THE TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

在线阅读下载PDF

导出

摘要目的　观察布地奈德雾化治疗在慢性阻塞性肺病 (COPD)急性加重期的临床疗效。方法　 60例COPD急性加重期住院患者随机分为 3组 ,分别给予布地奈德雾化治疗、泼尼松龙口服和空白对照治疗。观察 3组患者在第 2 4、72小时和第 7天的临床表现、肺功能和动脉血气变化以及副作用情况。结果　布地奈德组和泼尼松龙组的呼吸困难评分、FEV1 和动脉血气的改善程度均明显优于空白对照组 ,而布地奈德组和泼尼松龙组间无显著性差异。布地奈德组的副作用明显少于泼尼松龙组 ,与空白对照组相仿。结论　布地奈德雾化治疗是COPD急性加重期激素治疗的有效选择。 Objective: To evaluate the effect of Nebulized Budesonide(NB) in the treatment of acute exacerbations of chronic obstructive pulmonary disease (COPD). Methods: 60 patients with acute exacerbations of COPD in the stage Ⅱ were divided into 3 groups in random. The dyspnea score,postbronchodilator FEV_1,arterial blood gases analysis in H_0,H_ 24 ,H_ 72 ,D_7 were measured. And the adverse effect was evaluated at the same time. Results: The changes in postbronchodilator FEV_1,dyspnea score,PaCO_2 in the patients with active treatments were greater than those with placebo. The difference between NB and prednisolone group was no significant. Budesonide had less systemic activity than prednisolone as the placebo. Conclusion: Both NB and prednisolone improved airflow obstruction in COPD patients with acute exacerbations when compared with placebo. NB may be an alternative to oral prednisolone in the treatment of exacerbations of COPD.

作者韩伟周新

机构地区上海交通大学附属第一人民医院呼吸科

出处《实用临床医药杂志》 CAS 2004年第2期6-8,共3页 Journal of Clinical Medicine in Practice

关键词慢性阻塞性肺病急性加重期布地奈德泼尼松龙 chronic obstructive pulmonary disease acute exacerbation budesonide prednisolone

分类号 R562.1 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献10

1Pauwels R A,Buist A S,Calverley P M,et al.Global strategy for the diagnosis,management,and prevention of chronic obstructive pulmonary disease.NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary[J].Am J Respir Crit Care Med,2001,163(5):1256.
2Renkema T E,Schouten J P,Koeter G H,et al.Effects of long-term treatment with corticosteroids in COPD[J].Chest,1996,109(5):1156.
3Maltais F,Ostinelli J,Bourbeau J,et al.Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease:a randomized controlled trial[J].Am J Respir Crit Care Med,2002,165(5):698.
4Oudijk E J,Lammers J W,Koenderman L.Systemic inflammation in chronic obstructive pulmonary disease[J].Eur Respir J,2003,46(11):5.
5Niewoehner D E,Erbland M L,Deupree R H,et al.Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease[J].N Engl J Med,1999,340(25):1941.
6Davies L,Angus R M,Calverley P M A.Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease:a prospective randomized controlled trial[J].Lancet,1999,354(9177):456.
7Osman L M,Godden D J,Friend J A R,et al.Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease[J].Thorax,1999,52(1):67.
8Decramer M,Gosselink R,Troosters T,et al.Muscle weakness is related to utilization of health care resources in COPD patients[J].Eur Respir J,1997,10(2):417.
9McEvoy C E,Ensrud K E,Bender E,et al.Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med,1998,157(3):704.
10Johnell O,Pauwels R,Lofdahl C G,et al.Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler[J].Eur Respir J,2002,19(6):1058.